290
Participants
Start Date
August 1, 2014
Primary Completion Date
November 30, 2017
Study Completion Date
November 30, 2017
Double blind phase Placebo Nasal Spray
This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
double Blind Oxytocin Nasal Spray
Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.
Open Label intranasal oxytocin
All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin
Mount Sinai School of Medicine, New York
Center for Autism and the Developing Brain, White Plains
Duke Center for Autism and Brain Development, Durham
Duke University , Genetics Center, Durham
Vanderbilt University, Nashville
Seattle Children's Hospital Research Institute, Seattle
Lurie Center for Autism, Massachusetts General Hospital, Boston
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Linmarie Sikich
OTHER